Literature DB >> 8928888

Vascular endothelial growth factor administration in chronic myocardial ischemia.

K Harada1, M Friedman, J J Lopez, S Y Wang, J Li, P V Prasad, J D Pearlman, E R Edelman, F W Sellke, M Simons.   

Abstract

Vascular endothelial growth factor (VEGF) is a potent mitogen capable of stimulating angiogenesis. We examined the effect of VEGF administration in a model of chronic porcine myocardial ischemia. Nineteen pigs were instrumented with proximal left circumflex coronary artery (LCX) Ameroid constrictors. In eight animals VEGF (2 microgram) with heparin (50 U) was administered extraluminally to the LCX myocardium with an osmotic pump for 4 wk and 11 other animals served as controls. VEGF-treated animals demonstrated higher flow in the LCX territory during both rest and pacing compared with untreated controls (rest: 1.35 +/- 0.1 vs. 0.80 +/- 0.09 ml.min-1.g-1; pacing; 2.01 +/- 0.37 vs. 1.01 +/- 0.07 ml.min-1.g-1, P < 0.05, VEGF vs. controls). The observed improvement in regional coronary flow in VEGF-treated animals resulted in better preservation of endothelium-dependent microvessel relaxation as well as fractional LV shortening in the LCX territory during pacing in the VEGF-treated than in control animals (controls: 7.1 +/ 2.6 vs. 3.6 +/- 2.0%, rest vs. pacing; VEGF: 6.9 +/- 2.9 vs. 6.3 +/- 2.9%, rest vs. pacing). We conclude that VEGF administration in a gradual coronary occlusion model in pigs results in improvement of coronary flow and preservation of regional hemodynamics in the compromised myocardium.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8928888     DOI: 10.1152/ajpheart.1996.270.5.H1791

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  41 in total

1.  Targeted Coronary Thrombolysis via "Pericardial" Administration of Lytic Agents?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-09       Impact factor: 2.300

2.  Therapeutic Angiogenesis for Coronary Artery Disease.

Authors:  Tanveer A. Khan; Frank W. Sellke; Roger J. Laham
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-02

Review 3.  Epicardial gene therapy and laser revascularization.

Authors:  J F Symes
Journal:  Curr Cardiol Rep       Date:  1999-11       Impact factor: 2.931

4.  Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart.

Authors:  H Su; R Lu; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

5.  Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.

Authors:  Keiichi Kumasawa; Masahito Ikawa; Hiroyasu Kidoya; Hidetoshi Hasuwa; Tomoko Saito-Fujita; Yuka Morioka; Nobuyuki Takakura; Tadashi Kimura; Masaru Okabe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

6.  Stretch-induced VEGF expression in the heart.

Authors:  J Li; T Hampton; J P Morgan; M Simons
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

7.  Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation.

Authors:  Neel R Sodha; Richard T Clements; Munir Boodhwani; Shu-Hua Xu; Roger J Laham; Cesario Bianchi; Frank W Sellke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-12       Impact factor: 4.733

Review 8.  Imaging of angiogenesis in cardiology.

Authors:  Takahiro Higuchi; Hans Juergen Wester; Markus Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 9.236

Review 9.  Pharmacotherapy for end-stage coronary artery disease.

Authors:  Neel R Sodha; Louis M Chu; Munir Boodhwani; Frank W Sellke
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

Review 10.  Therapeutic myocardial angiogenesis.

Authors:  Marie-Ange Renault; Douglas W Losordo
Journal:  Microvasc Res       Date:  2007-09-07       Impact factor: 3.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.